Immune‐Related Adverse Events in the Setting of PD‐1/L1 Inhibitor Combination Therapy. (21st November 2019)

• Record Type: Journal Article
• Authors: Zubiri, Leyre; Allen, Ian M.; Taylor, Martin S.; Guidon, Amanda C.; Chen, Steven T.; Schoenfeld, Sara R.; Neilan, Tomas G.; Sise, Meghan E.; Mooradian, Meghan J.; Rubin, Krista M.; Leaf, Rebecca Karp; Parikh, Aparna R.; Faje, Alexander; Gainor, Justin F.; Cohen, Justine V.; Fintelmann, Florian J.; Kohler, Minna J.; Dougan, Michael; Reynolds, Kerry L.
• Is Part Of: Oncologist. Volume 25:Number 3(2020)
• Page Start: e398
• Page End: e404
• Publication Date: 2019-11-21
• Subjects: Immune checkpoint inhibitor -- Immune‐related adverse events -- Immunotherapy -- PD‐1/L1 inhibitor -- Immunotherapy toxicity; Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1634/theoncologist.2018-0883
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract : In 2018, a multi‐disciplinary workshop was held at the Massachusetts General Hospital to discuss challenges in defining, diagnosing, and treating immune‐related adverse events (irAE), including those that occur in patients administered PD‐1/L1 inhibitor combination therapy. In this commentary, the workshop participants present a clinical case that illustrates the complexity of irAE diagnosis and management in a patient receiving PD‐1/L1 combination therapy, summarize the current state of PD‐1/L1 combination therapy, and discuss challenges and opportunities for the evaluation of irAEs as these combinations become more widely used to treat patients with cancer.